Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00622193. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.
Study identification
- NCT ID
- NCT00622193
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 228 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2008
- Primary completion
- Nov 30, 2009
- Completion
- Nov 30, 2009
- Last update posted
- Apr 13, 2017
2008 – 2009
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| Osler Medical | Melbourne | Florida | 32901 | — |
| Augusta Oncology Associates | Augusta | Georgia | 30901 | — |
| South Georgia Medical Center | Valdosta | Georgia | 31602 | — |
| Investigative Clinical Research of Indiana | Indianapolis | Indiana | 46260 | — |
| John Hopkins University | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Center | Boston | Massachusetts | 02115 | — |
| Caritas St. Elizabeth's Medical Center | Boston | Massachusetts | 02135 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| The West Clinic | Corinth | Mississippi | 38834 | — |
| The West Clinic | Southaven | Mississippi | 38671 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| South Carolina Cancer Specialists | Hilton Head Island | South Carolina | 29926 | — |
| The West Clinic | Memphis | Tennessee | 38120 | — |
| Baylor College of Medicine/VAMC | Houston | Texas | 77030 | — |
| The Methodist Hospital Research Institute | Houston | Texas | 77030 | — |
| North West Medical Specialties, PLLC | Puyallup | Washington | 98372 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00622193, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2017 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00622193 live on ClinicalTrials.gov.